 FARMINGTON HILLS, Mich., May 11, 2022 GLOBE NEWSWIRE -- Ocuphire Pharma, Inc. Nasdaq: OCUP, a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced presentations by Mina Sooch, Founder and CEO, at the New Pathways in Retinal Diseases Panel at Retina World Congress RWC on May 12, 2022 and at H.C. Wainwright Global Investment Conference on May 24, 2022. Dr. David Lally will also be presenting masked safety data from Phase 2b APX3330 trial at RWC and Clinical Trials at the Summit on May 21, 2022. 